Vanguard Capital Management’s Pelthos Therapeutics PTHS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2M Sell
95,316
-1,818
-2% -$46.3K ﹤0.01% 3368
2026
Q2
$2.75M Buy
97,134
+4,041
+4% +$104K ﹤0.01% 3316
2026
Q1
$1.96M Buy
+93,093
New +$2.21M ﹤0.01% 3372

Other funds holding PTHS

Vanguard Capital Management's PTHS Position: Q3 2026 in Review

Vanguard Capital Management reduced its Pelthos Therapeutics (PTHS) stake by 1.9% in Q3 2026, selling an estimated $46.3K and leaving 95,316 shares worth $2M. The position accounts for ﹤0.01% of the portfolio, ranked #3368.

Vanguard Capital Management first reported a position in PTHS in Q1 2026 and has held it in 3 quarters since. The position peaked at $2.75M in Q2 2026. 29 funds tracked by Wall St. Rank hold PTHS as of Q3 2026.

  • Vanguard Capital Management held 95,316 shares of Pelthos Therapeutics worth $2M as of Q3 2026.
  • Vanguard Capital Management sold 1,818 Pelthos Therapeutics shares in Q3 2026, an estimated $46.3K.
  • Pelthos Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3368 holding.
  • Vanguard Capital Management first reported a position in Pelthos Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Pelthos Therapeutics position peaked at $2.75M in Q2 2026.
  • 29 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.